ReviewMethods in molecular biology (Clifton, N.J.)2025
RNA Therapeutics: Bridging Discovery and Clinical Implementation.
Review in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA-based therapeutics represents a groundbreaking class of pharmaceuticals that harness the diverse functions of RNA molecules for therapeutic intervention. Key approaches include ribozymes, RNA interference, CRISPR interference, and messenger RNAs. The clinical applications of these technologies have been catalyzed by advancements in chemical modifications and delivery approaches, such as ionizable lipid nanoparticles. One of the key advantages of RNA-based drugs is their ability to target virtually any genetic component within the cell, including those deemed undruggable by small drug molecules. This chapter offers an in-depth summary of current RNA technologies, including their targeting mechanisms, clinical progresses and the challenges involved in improving their delivery, efficacy, and safety.
Indexed as
Identifiers
40877498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.